We appreciate public comments bringing to our attention that in proposing to suppress the scoring of a measure, the effect of such action could be the antithesis of our goal of preventing an unfair and negative impact by unintentionally hindering the ability for a MIPS eligible clinician, eligible hospital, and CAH to achieve the maximum points available under the affected objective as well as the total score for the MIPS Promoting Interoperability performance category or the Medicare Promoting Interoperability Program
Article Title : [Not specified in the provided content] News Publication Date : [Not specified in the provided content] Web References : doi:10.1001/jamahealthforum.2025.4258 Keywords : Peptides, Agonists, Cohort studies, Racial differences, Ethnicity, Medications, Pharmaceuticals, Health care costs, Health insurance Tags: chronic disease management inequalitieseconomic factors in medication adherenceGLP-1 receptor agonists prescription disparitiesglycemic control and weight managementhealthcare equity in pharmaceutical accessmedication adherence in type 2 diabetesnon-Hispanic Black and Hispanic health disparitiesout-of-pocket costs for diabetes medicationspolicy implications for diabetes careprescription fill rates by demographicrace and ethnicity in diabetes treatmentsystemic barriers in healthcare access
Security & sovereignty Typically deployed on-prem or private cloud in air-gapped environments
Drug insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide
Rhubarb and fava beans have also been known to affect urine color
